1227 related articles for article (PubMed ID: 3104389)
1. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
3. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
Judd HL; Rigg LA; Anderson DC; Yen SS
J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
5. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
6. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
[TBL] [Abstract][Full Text] [Related]
7. Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease.
Mongioi A; Maugeri G; Macchi M; Calogero A; Vicari E; Coniglione F; Aliffi A; Sipione C; D'Agata R
Acta Endocrinol (Copenh); 1986 Feb; 111(2):228-34. PubMed ID: 3082098
[TBL] [Abstract][Full Text] [Related]
8. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
9. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
Chang RJ; Laufer LR; Meldrum DR; DeFazio J; Lu JK; Vale WW; Rivier JE; Judd HL
J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
[TBL] [Abstract][Full Text] [Related]
10. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
[TBL] [Abstract][Full Text] [Related]
11. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
[TBL] [Abstract][Full Text] [Related]
13. Effects of gonadotropin-releasing hormone administration on the pituitary-gonadal axis in male and female dogs before and after gonadectomy.
de Gier J; Buijtels JJ; Albers-Wolthers CH; Oei CH; Kooistra HS; Okkens AC
Theriogenology; 2012 Mar; 77(5):967-78. PubMed ID: 22153274
[TBL] [Abstract][Full Text] [Related]
14. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
[TBL] [Abstract][Full Text] [Related]
15. The rapid ovarian secretory response to pituitary stimulation by the gonadotropin-releasing hormone agonist nafarelin in sexual precocity.
Rosenfield RL; Garibaldi LR; Moll GW; Watson AC; Burstein S
J Clin Endocrinol Metab; 1986 Dec; 63(6):1386-9. PubMed ID: 2946712
[TBL] [Abstract][Full Text] [Related]
16. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
[TBL] [Abstract][Full Text] [Related]
17. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
[TBL] [Abstract][Full Text] [Related]
18. Chronic hyperestrogenemia: lack of positive feedback action on gonadotropin-releasing hormone-induced luteinizing hormone release and dual site of negative feedback action.
Richardson DW; Gordon K; Billiar RB; Little AB
Endocrinology; 1992 Mar; 130(3):1090-6. PubMed ID: 1537275
[TBL] [Abstract][Full Text] [Related]
19. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
[TBL] [Abstract][Full Text] [Related]
20. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis.
Meldrum DR; Chang RJ; Lu J; Vale W; Rivier J; Judd HL
J Clin Endocrinol Metab; 1982 May; 54(5):1081-3. PubMed ID: 6801075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
